Evidence required to evaluate the use of bacteriologically confirmed asymptomatic tuberculosis disease as a primary endpoint in prevention of tuberculosis disease vaccine licensure trials

Overview of attention for article published in The Lancet Respiratory Medicine, July 2025

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

twitter: 12 X users

bluesky: 16 Bluesky users

Readers on

mendeley: 17 Mendeley

So far, Altmetric has seen 16 Bluesky posts from 16 Bluesky users, with an upper bound of 8,368 followers.

Open Access UCL Research: Evidence required to evaluate the use of bacteriologically confirmed asymptomatic tuberculosis disease as a primary endpoint in prevention of tuberculosis disease vaccine licensure trials discovery.ucl.ac.uk/id/eprint/10...

RP @kchorton.bsky.social: In our latest personal view in @lancetrespirmed.bsky.social, we argue for the inclusion asymptomatic #tuberculosis in vaccine trial endpoints to potentially reduce the size, length, and cost of trials. doi.org/10.1016/S221...…

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity, including 12 additional Bluesky posts.